OMNIA 5 mg is a medication manufactured by Incepta Pharmaceuticals Ltd., containing mavacamten. It is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
The usual starting dose is 5 mg once daily, which may be adjusted based on the patient's response and tolerance. It is essential to follow the prescribing healthcare provider's instructions regarding dosage and administration.